We are live on ! Find out more
SNDX icon

Syndax Pharmaceuticals
SNDX

71 hedge funds and large institutions have $160M invested in Syndax Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 32 increasing their positions, 13 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

146% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 13

79% more capital invested

Capital invested by funds: $89.1M → $160M (+$70.8M)

57% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 7

50% more call options, than puts

Call options by funds: $929K | Put options by funds: $621K

3% more funds holding

Funds holding: 69 → 71 (+2)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

4.5% less ownership

Funds ownership: 67.88% → 63.37% (-4.5%)

Holders
71
Holders Change
+2
Holders Change %
+2.9%
% of All Funds
1.54%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
11
Increased
32
Reduced
13
Closed
7
Calls
$929K
Puts
$621K
Net Calls
+$308K
Net Calls Change
+$8K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$1.34M
2
Renaissance Technologies
Renaissance Technologies
New York
+$855K
3
N
Nuveen
North Carolina
+$796K
4
State Street
State Street
Massachusetts
+$595K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$589K

Top Sellers

Rank Fund Capital Flow
1
BI
BVF Inc
California
-$1.62M
2
TCM
Tekla Capital Management
Massachusetts
-$753K
3
OAM
Oxford Asset Management
United Kingdom
-$569K
4
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$547K
5
Bank of America
Bank of America
North Carolina
-$519K
Name Holding Trade Value Shares
Change 		Change in
Stake
Wellington Management Group
1
Wellington Management Group
Massachusetts
$30.5M -$296K -40,590 -1%
MAM
2
MPM Asset Management
Massachusetts
$20.2M – – –
BI
3
BVF Inc
California
$16.4M -$1.62M -222,885 -11%
BlackRock
4
BlackRock
New York
$15.7M +$1.34M +183,872 +12%
6CM
5
683 Capital Management
New York
$15M +$128K +17,598 +1%
Adage Capital Partners
6
Adage Capital Partners
Massachusetts
$13.7M -$547K -75,000 -5%
Vanguard Group
7
Vanguard Group
Pennsylvania
$9.58M +$589K +80,761 +9%
Dimensional Fund Advisors
8
Dimensional Fund Advisors
Texas
$8.79M +$267K +36,597 +4%
Renaissance Technologies
9
Renaissance Technologies
New York
$4.02M +$855K +117,300 +37%
State Street
10
State Street
Massachusetts
$3.02M +$595K +81,628 +34%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$2.5M +$517K +70,951 +36%
SI
12
Sofinnova Investments
California
$2.26M +$214K +29,370 +14%
O
13
OrbiMed
New York
$1.97M – – –
PAM
14
Panagora Asset Management
Massachusetts
$1.84M +$365K +50,030 +34%
Northern Trust
15
Northern Trust
Illinois
$1.75M +$83.6K +11,470 +6%
Macquarie Group
16
Macquarie Group
Australia
$1.68M – – –
USAA
17
United Services Automobile Association
Texas
$1.15M +$8.24K +1,130 +0.9%
N
18
Nuveen
North Carolina
$1.02M +$796K +109,232 New
Bank of New York Mellon
19
Bank of New York Mellon
New York
$659K +$35.3K +4,837 +7%
Morgan Stanley
20
Morgan Stanley
New York
$566K -$53.8K -7,381 -11%
OAM
21
Oxford Asset Management
United Kingdom
$544K -$569K -78,038 -57%
Charles Schwab
22
Charles Schwab
California
$468K +$94.4K +12,947 +35%
Millennium Management
23
Millennium Management
New York
$382K -$190K -26,078 -39%
Bank of America
24
Bank of America
North Carolina
$371K -$519K -71,138 -64%
CCIA
25
Campbell & Co Investment Adviser
Maryland
$367K +$287K +39,372 New
1
2 3 4

SNDX Hedge Fund Activity: Q2 2019 in Review

71 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q2 2019, worth a combined $160M — up 79% from $89.1M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new SNDX positions and 7 closed out — a net gain of 4 holders — while 32 added to existing stakes and 13 trimmed.

The largest buyer was BlackRock, adding an estimated $1.34M. The largest seller was BVF Inc, cutting an estimated $1.62M.

  • 71 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q2 2019, up from 69 in Q1 2019.
  • Funds reported $160M of Syndax Pharmaceuticals stock for Q2 2019, up 79% quarter-over-quarter.
  • 11 funds opened new Syndax Pharmaceuticals positions in Q2 2019 and 7 closed out, a net change of +4 holders.
  • The largest Syndax Pharmaceuticals buyer in Q2 2019 was BlackRock, an estimated $1.34M added.
  • The largest Syndax Pharmaceuticals seller in Q2 2019 was BVF Inc, an estimated $1.62M sold.

Based on aggregated 13F filings for Q2 2019.